The SMYD3/HER2 link is clinically relevant because of the abnormal HER2 activation involved in development and progression of various types of cancers: namely, HER2 amplification is observed in 18–25% of BrCA and correlates with poor prognosis (Table 2) [48]. Here, ERBB2 is linked to cancer.